DIRS.INFO The most relevant business & tech news

A vial labelled "Novavax V COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. Still, the Maryland-based biotech, which has been banking on cost cuts and commercial sales of its retooled COVID shot to help it stay afloat, reiterated its "going concern warning". The company expects the 2023-2024 U.S. market for COVID shots to be between 30 million and 50 million doses. The company's updated COVID shot, using a more traditional technology than the mRNA-based vaccines of rivals Pfizer (PFE.N) and Moderna (MRNA.O), was authorized in the U.S. in October. Novavax missed out on the COVID vaccine windfall that benefited rivals due to manufacturing issues that delayed its filing for approval when the pandemic was raging.

Persons: Dado Ruvic, Novavax, Jim Kelly, John Jacobs, Jacobs, Bhanvi, Patrick Wingrove, Sriraj Kalluvila, Bill Berkrot Organizations: REUTERS, U.S, Department of Health, Human Services, Pfizer, Moderna, Thomson Locations: Maryland, U.S, United States, Bengaluru, New York

☆ October slammed biotech stocks, and these 3 hedge funds couldn't escape the pain
▼ + stars: | 2023-11-08 | by ( Bradley Saacks | ) www.businessinsider.com time to read: +1 min

Biotech hedge funds couldn't escape a tough October, sources told Insider. Managers like Perceptive Advisors and RTW Investments lost more than 9% in just a month's time. While big-name hedge funds were able to avoid some of the market's pain last month, biotech specialists were hit hard. Some funds, including Perceptive Advisors, RTW Investments, and San Francisco-based Redmile Group, had a tough October thanks to pain across the biotech space, according to sources familiar with their performance. The flagship fund at $8 billion Perceptive Advisors, run by billionaire Joseph Edelman, lost 9.5% in the month, bringing its yearly performance to a loss of 8.7%.

Persons: Joseph Edelman, Davidson Kempner, Roderick Wang Organizations: Biotech, RTW Investments Locations: Moderna, San Francisco

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Amazon, Uber, Coinbase, Carvana, Starbucks & more
▼ + stars: | 2023-11-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Here are Friday biggest calls on Wall Street: Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's standing by Apple shares after its earnings report on Thursday. Berenberg downgrades Estee Lauder to hold from buy Berenberg downgraded the stock after its disappointing earnings report earlier this week. Morgan Stanley reiterates Carvana as underweight Morgan Stanley said it's sticking with its underweight rating on the stock after its earnings report on Thursday. " Evercore ISI downgrades Fortinet to in line from outperform Evercore downgraded the cybersecurity company after its earnings report. JPMorgan reiterates Starbucks as overweight JPMorgan said the coffee giant is "still one to buy" after its earnings report on Thursday. "

Persons: Morgan Stanley, Apple, it's, downgrades Estee Lauder, Estée Lauder, Piper Sandler, Piper, OMCL, Key, Wolfe, Mizuho, C27E, JPMorgan downgrades, Papa John's, PZZA, Raymond James, Carvana, CVNA, Redburn, JPMorgan, SBUX, Guggenheim, GNRC Organizations: Apple, DOJ, Uber, Deutsche Bank, Molson Coors, Deutsche, HSBC, Moderna, Nvidia, Mizuho, JPMorgan, JPMorgan downgrades Fox, FOX, Barclays, Retail, Evercore, billings, Guggenheim, Citi, Cedar, Flags, ~$

HONG KONG (AP) — Asian shares advanced on Friday after Wall Street roared higher on bets that market-rattling interest rate hikes are coming to an end. On Wall Street, the S&P 500 leaped 1.9% Thursday to 4,317.78 for its fourth straight winning day. Starbucks jumped 9.5% after reporting stronger profit and revenue for the latest quarter than Wall Street forecast. On the losing end of Wall Street was Moderna, which sank 6.5% after reporting a much worse loss for the latest quarter than analysts expected. More swings could be coming for Wall Street.

Persons: Seng, Australia’s, Korea’s Kospi, Sensex, It’s, Jerome Powell, Eli Lilly's, Brent Organizations: Shanghai, Federal Reserve, Dow Jones Industrial, Nasdaq, Big U.S, Starbucks, Fair, Moderna, Wall, New York Mercantile Exchange, U.S . Locations: HONG KONG, Tokyo, China, U.S

☆ Restaurant stocks McDonald's and Chipotle could be due for a pullback after the market's rally this week
▼ + stars: | 2023-11-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

The stock market is enjoying its best week of 2023, but some names may have gotten ahead of themselves. That said, some stocks have become overbought during this week's rally — and could be due for a pullback. MCD YTD mountain McDonald's stock Beverage company Coca-Cola was another one of the several consumer names on this week's overbought list. Here are the 10 most oversold names in the broad market index: Several health-care companies were among this week's most oversold stocks. SEDG 1D mountain SolarEdge shares Revvity, Henry Schein, Align Technology and Fortive are some of the other oversold names from this week.

Persons: McDonald, Kraft Heinz, Amgen, David Palmer, CNBC's, Dr Pepper, SolarEdge, Zvi Lando, Henry Schein Organizations: Dow Jones, Nasdaq, PayPal, Pfizer, CNBC, Beverage, PepsiCo, Monster Beverage, Grill, Darden, Moderna, Enphase Energy, SolarEdge Technologies, Technology Locations: U.S, Europe

☆ Stocks making the biggest moves premarket: Starbucks, Shopify, Roku and more
▼ + stars: | 2023-11-02 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Starbucks — Shares of the coffee giant jumped 5.6% after Starbucks' quarterly earnings and revenue exceeded analysts' expectations. The company reported third-quarter earnings of 24 cents per share, excluding items, on revenue $1.71 billion. Analysts polled by FactSet expected earnings of 15 cents per share on revenue of $1.67 billion. Qualcomm — Shares of the wireless tech company gained 5.6% after Qualcomm surpassed analysts' revenue and earnings estimates in its fiscal fourth quarter. Analysts had been expecting a loss of 40 cents per share on $2.09 billion revenue, according to LSEG.

Persons: SolarEdge, Shopify, FactSet, DoorDash, LSEG, Lyft, Airbnb's, Moderna, CNBC's Hakyung Kim, Jesse Pound, Michelle Fox Theobald Organizations: Starbucks, Truist, BMO Capital Markets, Guggenheim, Qualcomm —, Qualcomm, Wall Street, —, Moderna — Locations: New York

☆ Stock Market News Today: Dow Gains 400 Points; Apple, Starbucks Earnings in Focus
▼ + stars: | 2023-11-02 | by ( ) www.wsj.com time to read: +1 min

Bond yields fell significantly for a second day. Major stock indexes jumped. Shares jumped after the coffee shop chain's earnings topped estimates. Roku shares rose some 30%. Benchmark 10-year Treasury yields fell below 4.7%, after trading near 5% last week.

Persons: Stocks, Jerome Powell, Dow, Brent Organizations: Federal, Novo Nordisk, Fed, Bank of England, Starbucks

☆ Moderna CEO Stephane Bancel on Q3 results
▼ + stars: | 2023-11-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna CEO Stephane Bancel on Q3 resultsModerna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, and more.

Persons: Stephane Bancel Organizations: Email Moderna

☆ Stocks making the biggest moves midday: Starbucks, Roku, Eli Lilly, Affirm and more
▼ + stars: | 2023-11-02 | by ( Hakyung Kim | ) www.cnbc.com time to read: +5 min

Starbucks — Shares jumped 9.5% after the company posted an earnings and revenue beat in the fiscal fourth quarter. Palantir also raised its revenue guidance to between $2.216 billion and $2.22 billion for the full year. Clorox — Shares rallied more than 6.6% Thursday after the company posted an earnings and revenue beat in the fiscal first quarter. CyberArk's fourth-quarter and full-year earnings guidance also came in above analysts' estimates. Management lowered the company's full-year earnings, revenue and operating margins guidance.

Persons: Roku, SolarEdge, Shopify, Palantir, LSEG, Eli Lilly —, —, Penn, Morgan Stanley, CyberArk's, Papa John's, Sarah Min, Yun Li, Michelle Fox, Pia Singh, Alex Harring Organizations: Starbucks —, Management, Truist, BMO Capital Markets, Guggenheim, Moderna —, Moderna, Penn Entertainment, ESPN, Amazon Business, Marriott, Rockwell Automation — Rockwell Automation Locations: China, America

☆ Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
▼ + stars: | 2023-11-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shotsCNBC's Becky Quick reports on the company's quarterly earnings results.

Persons: Becky Quick Organizations: Moderna

☆ Moderna stock falls 10% as hefty Covid vaccine write-downs drive big loss
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Thursday posted a steep loss for the third quarter as the drugmaker recorded a large write-down due to unused doses of its Covid vaccine, its only marketable product. Revenue: $1.83 billion vs. $1.40 billion expectedShares of Moderna fell more than 10% in premarket trading Thursday. Moderna posted a net loss of $3.63 billion, or $9.53 per share, for the quarter. The biotech company generated third-quarter sales of $1.83 billion, with sales of its Covid shot dropping 44% from the same period a year ago. In August, Moderna said it expected its shot to rake in $6 billion to $8 billion in revenue in 2023.

Persons: Stéphane Bancel, Bancel, Moderna Organizations: Moderna, LSEG, Revenue Locations: U.S

☆ Stock Market Today: Dow Closes 500 Points Higher; Apple, Starbucks Earnings in Focus
▼ + stars: | 2023-11-02 | by ( ) www.wsj.com time to read: +1 min

Bond yields fell significantly for a second day. Major stock indexes jumped. Its shares jumped after the coffee shop chain's earnings topped estimates. The vaccine maker fell more than 6% after reporting a sharp drop in profits. Benchmark 10-year Treasury yields fell below 4.7%, settling at 4.668%, after trading near 5% last week.

Persons: Stocks, Jerome Powell, Dow, Brent Organizations: Federal, Novo Nordisk, Fed, Bank of England, Starbucks

☆ Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
▼ + stars: | 2023-11-01 | by ( Khushi Mandowara | ) www.reuters.com time to read: +3 min

Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. Around 20 million people need to be vaccinated with Moderna's updated COVID-19 vaccine for the company to reach $2 billion in 2023 sales from the private market, a figure four analysts told Reuters was achievable. The company has said it expects total U.S. COVID vaccine demand to be as much as 100 million doses in the fall season. Moderna forecast $6 billion to $8 billion for sales of its COVID-19 vaccine in 2023, $2 billion to $4 billion of which is expected to come from the commercial market. The COVID vaccine is Cambridge, Massachusetts-based Moderna's lone marketed product.

Persons: Dado Ruvic, Oppenheimer, Hartaj Singh, Michael Yee, Yee, Manas Mishra, Khushi, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, Reuters, U.S, Moderna, Pfizer, Jefferies, GSK, Thomson Locations: Cambridge , Massachusetts, United States, Bengaluru, New

☆ Never Mind Covid, Investors Want a Pfizer Obesity Pill
▼ + stars: | 2023-10-31 | by ( David Wainer | ) www.wsj.com time to read: +1 min

Pfizer says it hasn’t gotten the data on its experimental oral obesity medication. It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush , a healthcare strategist for Jefferies. Before today’s earnings, David Risinger , a Leerink Partners analyst, had written that Pfizer might even release data from its midstage study alongside the earnings results as soon as Tuesday.

Persons: hasn’t, Gabby Jones, Eli Lilly, ”, Will Sevush, Jefferies, David Risinger, Albert Bourla, TD Cowen, Steva Scala Organizations: Pfizer, The Wall, Novo Nordisk, Moderna, Partners

☆ Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
▼ + stars: | 2023-10-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Tuesday reported a narrower-than-expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and the Covid vaccine. Pfizer said it recorded a $5.6 billion charge for inventory write-offs in the third quarter due to lower-than-expected use of Covid products. Of these write-offs, $4.7 billion is chalked up to Paxlovid and $900 million is attributed to the company's vaccine. For the third quarter, Pfizer booked a net loss of $2.38 billion, or 42 cents per share. Meanwhile, the pharmaceutical giant expects its Covid antiviral treatment Paxlovid to bring in $1 billion in revenue.

Persons: Paxlovid Organizations: Pfizer, LSEG, U.S . Locations: U.S, Monday's

☆ Asia stocks mull over Middle East, central bank meetings
▼ + stars: | 2023-10-30 | by ( Wayne Cole | ) www.reuters.com time to read: +5 min

The earnings season also continues with Apple, Airbnb, McDonald's, Moderna and Eli Lilly & Co among the many reporting this week. Early on Monday, S&P 500 futures had edged up 0.3% to 4,151, while Nasdaq futures added 0.5%. Japan's Nikkei (.N225) fell 1.1% amid speculation the Bank of Japan (BOJ) might tweak its yield curve control (YCC) policy after its two-day policy meeting wraps up on Tuesday. The Bank of England is also expected to stay on hold this week, with markets pricing around a 70% chance it is done tightening altogether. Oil prices eased as worries about demand outweighed risks to Middle East supplies, at least for the moment.

Persons: Issei Kato, BoE, BOJ, Eli Lilly, China Evergrande, Treasuries, Goldman Sachs, reacceleration, Brent, Wayne Cole, Jamie Freed Organizations: REUTERS, Nikkei, Apple, Moderna, Nasdaq, HK, Japan's Nikkei, Bank of Japan, Barclays, Treasury, NatWest, Federal Reserve, Bank of England, Capital, Thomson Locations: Tokyo, Japan, U.S, Gaza, payrolls SYDNEY, United States, Britain, McDonald's, Gaza's, Iranian, Asia, Pacific, China, Israel, East

☆ Morning Bid: Markets hold their nerve amid Mid East trouble
▼ + stars: | 2023-10-30 | by ( Wayne Cole | ) www.reuters.com time to read: +3 min

Oct 30 (Reuters) - A look at the day ahead in European and global markets from Wayne Cole. Most talk is it will stay on hold this time, but will discuss laying the groundwork for an eventual shift. Any tweak would see Japanese yields rise and add to the pain being felt in the Treasury market, where 10-year yields nudged up to 4.87% on Monday with scant sign of any safe haven bid. Analysts at NatWest Markets expect $885 billion of marketable borrowing in Q4 and $700 billion in Q1. It is also notable that the borrowing kept climbing even though the economy surprised everyone with its strength.

Persons: Wayne Cole, It's, Eli Lilly, Luis de Guindos, Erik Thedéen, Muralikumar Organizations: Nikkei, Bank of Japan, Ichi, Insurance, Reuters, Treasury, NatWest Markets, Federal Reserve, Apple, Thomson Locations: Wayne, Gaza, China

☆ How the Fed is using its multi-trillion-dollar balance sheet to fight inflation
▼ + stars: | 2023-10-29 | by ( Bryan Mena | ) edition.cnn.com time to read: +9 min

Washington, DC CNN —The Fed’s fight against inflation is about to enter a new phase, but the central bank’s enormous balance sheet will continue to play a key role. The Fed also manages a multi-trillion-dollar balance sheet that accounts for trillions in government securities and lists how much currency is in circulation. For over a year now, the Fed has been steadily shrinking its balance sheet to help cool the economy. The Fed’s balance sheet is currently at around $7.9 trillion, down from its peak of $9 trillion in early 2022 right before the runoff. They also see alternative scenarios for the end of the balance sheet runoff if there isn’t a recession.

Persons: that’s, Lael Brainard, What’s, Wells, Jerome Powell, JPMorgan Chase’s Jamie Dimon, Jamie Dimon, Krystal Hur, Dimon —, Mr, Dimon, JPMorgan Chase, what’s, Estee Lauder, Kraft Heinz, Yum, Bausch, Eli Lilly, Molson Organizations: CNN Business, Bell, DC CNN, Congress, Fed, Wall Street, JPMorgan, JPMorgan Chase, CNN, HSBC, McDonald’s, China’s National Bureau of Statistics, Bank of Japan, Pfizer, Caterpillar, Marathon Petroleum, Sirius XM, Anheuser, Busch, BP, Chesapeake Energy, US Labor Department, Global, Board, CVS, GSK, Humana, Reuters, Apollo Global Management, Brands, Garmin, Cruise Line Holdings, Qualcomm, Airbnb, PayPal, MetLife, Aflac, AIG, Allstate, Prudential, P Global, Institute for Supply Management, Federal Reserve, ConocoPhillips, Starbucks, Duke Energy, Shopify, Ferrari, Marriott International, Moderna, Fox, Molson Coors, Hyatt, Apple, Motorola, Bank of England, Dominion Energy, Gartner, Restaurant Brands Locations: Washington, Treasuries, China’s, Mondelez, DoorDash, Avis, Shell, Cigna

☆ Jamie Dimon's stock-moving trades show why investors should track CEOs' buying and selling
▼ + stars: | 2023-10-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +24 min

While executive stock sales — such as Dimon's planned transactions next year — are not universally red flags, they can get complicated. Insider stock sales Executive stock trades are usually disclosed through SEC filings known as Form 4 documents and accessible through the regulator's EDGAR database — the electronic data gathering, analysis, and retrieval system. Rule 10b5-1 trading plans came into the fold just over two decades ago to reconcile these two discordant facts. Adopting Rule 10b5-1 trading plans gives public-company executives a way to protect against allegations of illegal insider trading in the future. Compared with a tiny stock sale executed through a predetermined plan, executive stock buys generally send a much stronger signal: The executive wants to make money, too.

Persons: Jamie Dimon, Dimon, Jim Cramer, Jim, Eliezer Fich, Dimon's, EDGAR, Chester Spatt, Spatt, —, Susan Li, Drexel's, Wharton, Drexel's Fich, Fich, I'm, Nancy Quan's, Quan, Marc Benioff, Carnegie Mellon's Spatt, Benioff, Howard Schultz, Schultz's, Schultz, Carnegie Mellon's, Nikesh Arora, Arora, Charles Scharf, Wells, Sehwa Kim, Kim, Foot, Mary Dillon, Locker, Dillon, Foot Locker, Jim Cramer's, Al Drago Organizations: JPMorgan Chase, JPMorgan, Dow Jones Industrial, Wall, Dimon, Pfizer, Capitol, Drexel University, Club, Securities, Exchange Commission, SEC, Carnegie Mellon's Tepper School of Business, CNBC, Stanford University, University of Pennsylvania's Wharton School, Stanford, Cola, Salesforce, Carnegie, Starbucks, Palo Alto Networks, Alto Networks, Broadcom, Federal Reserve, Washington Service, Columbia Business School, JPMorgan Chase &, Bloomberg, Getty Locations: U.S, Coke, Salesforce, FL

☆ Jobs and earnings are major themes next week as we consider more portfolio moves
▼ + stars: | 2023-10-28 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

But in the end, it's fundamentals that drive earnings and earnings that drive stock prices. Looking ahead to next week, we'll get several important macroeconomic updates along with nine Club earnings reports. Economic releases Next week is Jobs Friday when we get the government's monthly nonfarm payrolls report. Club stock earnings Club name Caterpillar (CAT) reports third-quarter results before the opening bell Tuesday. DuPont (DD) is set to report earnings.

Persons: it's, we'll, nonfarm payrolls, We'll, Estee Lauder, Eli Lilly, BUD, Jerome Powell, Kraft Heinz, WEN, Papa John's, Dwight Co, Jim Cramer's, Jim Cramer, Jim, Brendan Mcdermid Organizations: Caterpillar, GE Healthcare, DuPont, Bausch Health, Starbucks, Apple Watch, VF Corp, GE HealthCare, Pfizer, JetBlue, Anheuser, Busch InBev, Devices, Caesars Entertainment, Cruise, CVS Health, Brinker International, Yum Brands, PayPal, Qualcomm, Mondelez, Novo Nordisk, Barrick, Penn Entertainment, Paramount Global, Marriott, Ferrari, Molson Coors, TAP, Coinbase, Natural Resources, Booking Holdings, International, Monster Beverage, Health, Resources, Dwight, Restaurant Brands, Sempra Energy, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange Locations: North America, China, New York City, U.S

☆ These stocks reporting next week typically beat the Street and rally
▼ + stars: | 2023-10-27 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

The following stocks have beat analyst expectations at least 85% of the time and rise at least 1% on average after they release their earnings results, per data from Bespoke Investment Group. The company has managed to beat earnings and revenue estimates 96% and 89% of the time, respectively. ANET YTD mountain ANET in 2023 Workiva Workiva is another cloud software company that made the cut. Workiva also has a strong history of outperforming estimates, with 100% and 97% earnings and revenue beat rates, respectively. Workiva shares have tumbled about 16% from their year-to-date highs in September, paring some of the stock's year-to-date gains down to 12.5%.

Persons: Eli Lilly, Goldman Sachs, We're, Michael Ng, Workiva, paring, — CNBC's Michael Bloom Organizations: Apple, Moderna, PayPal, Starbucks . Companies, CNBC Pro, Investment, Apple Investors, JPMorgan, Arista Networks, Evercore ISI Locations: China

☆ The Fed decision and jobs report are in the week ahead as Wall Street wraps up a brutal month
▼ + stars: | 2023-10-27 | by ( Sarah Min | ) www.cnbc.com time to read: +7 min

The Federal Reserve meeting and October jobs report are on the docket next week as investors wrap up a brutal month for markets. Both the S & P 500 and Nasdaq Composite slid into correction territory this week following some disappointing megacap tech reports. "I suspect that the Fed is not going to comfort the market," said James Camp, managing director at Eagle Asset Management. Many investors expect stocks could remain choppy until the markets gain clarity on when the Fed will start to cut rates. Jobs report Investors will get another look into the labor market next week soon after the Fed decision.

Persons: Jerome Powell, James Camp, Dave Sekera, Sekera, Dow Jones, Nick Galluccio, you'll, Powell, Charlie Ripley, Ripley, Galluccio, we've, Eli Lilly Organizations: Reserve, Nasdaq, Eagle Asset Management, Fed, Teton Advisors, Treasury, Asset, Apple, Investors, Allianz Investment Management, Advisors, Dallas Fed, Simon Property, Semiconductor, Western, ECI Civilian Workers, Chicago PMI, Devices, Caesars Entertainment, Pfizer, GE Healthcare Technologies, Caterpillar, ADP, PMI, Manufacturing, Costco Wholesale, Qualcomm, Cruise Line Holdings, Brands, Labor, Factory, News Corp, Booking Holdings, Paramount Global, Moderna, Jobs, Services PMI, Health Locations: U.S, FactSet, Chicago

☆ Here are the most oversold stocks due for a bounce following the market's tough week
▼ + stars: | 2023-10-27 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

The Nasdaq and the S & P 500 are each on pace for declines of about 2.5%. Some stocks hit by this week's losses have become oversold — and could be due for a bounce. Align Technology , another company that has taken a heavy beating to its stock price this week, could also be due for a comeback, based on analysts' price targets. The company's third-quarter results fell short of analysts' expectations , and a slate of analysts cut their price targets following the release. Analysts covering the stock forecast a 4.6% upside for the company's stock price, and less than 30% rate it a buy.

Persons: bode, Kevin Caliendo, Tesla, Henry Schein, Lockheed Martin, RTX, Greg Hayes, — CNBC's Michael Bloom Organizations: Tesla, Moderna, Nasdaq, Dow Jones, CNBC, Technology, UBS, Southwest Airlines, Aerospace, Lockheed, Dollar, Dwight, Marathon Oil, Allstate Locations: Covid, Ukraine, Israel

☆ Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data
▼ + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. Covid vaccine rates in the U.S. were bleak last year, and could look the same this year. The trial measured the safety, tolerability and efficacy of Pfizer's combination vaccine candidates among adults ages 18 to 64. The results showed that "lead" formulations of Pfizer's combination vaccine demonstrated robust immune responses to influenza A, influenza B and Covid strains, according to Pfizer. The safety profiles of the combination vaccine candidates were also consistent with the company's Covid vaccine.

Persons: BioNTech, Annaliesa Anderson, Pfizer's, Albert Bourla Organizations: Pfizer, BioNTech, Moderna Locations: U.S

Moderna on Tuesday announced that its combination shot for flu and COVID-19 is the first candidate to make it to late-stage trial. It “offers greater convenience and has the potential to lead to increased compliance with vaccine recommendations,” it added. The shots won’t be available for this respiratory virus season, as Moderna said it is targeting regulatory approval for the shot in 2025. Moderna earlier this month announced positive data from its earlier studies of the combo shot, finding that it produced an immune response similar to or greater than licensed flu shots and Moderna’s bivalent COVID-19 shot. “We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses.”

Persons: “, Moderna, bivalent, Stéphane Bancel Organizations: Moderna, Tuesday, Northern Hemisphere, Disease Control, ” Moderna Locations: Moderna

Search resuls for: "modernă"

25 mentions found